pf-07817883
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Oct 17, 2022 (NCT05580003)
Timeline
Indications
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N[C@H](C(=O)N1C[C@H](C(F)(F)F)C[C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C(C)(C)C- Mol. weight
- 489.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5591580 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07235137 | Phase 1 | Oct 16, 2025 | Pfizer |
| NCT07013474 | Phase 3 | Jul 14, 2025 | Pfizer |
| NCT06837259 | Phase 1 | Mar 21, 2025 | Pfizer |
| NCT06679140 | Phase 3 | Dec 16, 2024 | Pfizer |
| NCT06646042 | Phase 1 | Oct 28, 2024 | Pfizer |
| NCT06586216 | Phase 1 | Sep 10, 2024 | Pfizer |
| NCT06122194 | Phase 1 | Nov 23, 2023 | Pfizer |
| NCT05884554 | Phase 1 | Jun 15, 2023 | Pfizer |
| NCT05799495 | Phase 2 | May 24, 2023 | Pfizer |
| NCT05822440 | Phase 1 | Apr 13, 2023 | Pfizer |
| NCT05580003 | Phase 1 | Oct 17, 2022 | Pfizer |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 11 | 11 | 3 | 2022 |
1 organizations
Page 1 / 1